Site MapContact Us
CompanyProduct PlatformInvestorsNewsCareers

DEVELOPING A NEW CLASS OF SYNTHETIC VACCINES

Selecta is developing first-in-class integrated synthetic nanoparticle vaccines using its proprietary targeted Synthetic Vaccine Particle (tSVP™) technology. These synthetic vaccines mimic the structure of natural pathogens with regards to size, shape and the sequence of immunological information for highly-effective targeting to immune cells to produce an optimal immune response. Selecta’s novel synthetic nanoparticle vaccines enable expanded opportunities for both the treatment and prevention of a wide range of human diseases including infectious, CNS, metabolic and inflammatory diseases.

Learn More blue_arrow

News

  • Selecta Biosciences, Inc. Closes $15 Million Series C Financing. Read More red_arrow
  • Selecta Biosciences, Inc. Co-Founder Named 2009 Mass High Tech All Star. Read More red_arrow
  • Selecta Biosciences, Inc. Closes $15.1M Series B Financing. Read More red_arrow
  • Selecta Biosciences Forms Distinguished Scientific Advisory Board. Read More red_arrow
  • Selecta Biosciences Appoints Lloyd Johnston, Ph.D., as Vice President, Pharmaceutical Research and Development. Read More red_arrow

Careers

© 2010 Selecta Biosciences, Inc.  |  480 Arsenal St., Building One, Watertown, MA 02472  |  Phone: 617-923-1400  |   Fax: 617-924-3454  |  Email: info@selectabio.com
Privacy Policy  |  Web site designed and developed by RainCastle Communications, Inc.